Echeverri MMA, Aristizábal DAM, Vargas F, Molina JF, Fernando PL, Zuluaga DA

Language: Spanish
References: 30
Page: 7-17
PDF size: 307.35 Kb.

ABSTRACT

Psoriasis is a common, multifactorial, chronic inflammatory disease that affects 1-3% of the world population. It is characterized by abnormal proliferation of keratinocytes due to a persistent stimulation of T cells by epidermic immunogens. There are multiple treatments such as topic and systemic therapy with variable results. Recently new therapies directed against adhesion molecules, activation and migration of T lymphocytes, and their products like cytokines, have been developed and play an important role in the pathogenesis of this disease. The Food Drug Administration (FDA) has approved Alefacept, an antibody directed against CD2, Efalizumab, a monoclonal antibody that block the interaction between Leucocitary Funtion Antigen 1 (LFA-1) to Interercellular Adhesion Molecule 1 (ICAM-1) and Etanercept, a Tumoral Necrosis Factor α (TNFα) receptor fusion protein, for the use in psoriasis and psoriatic arthritis. Even though they appear to be promising medications, close attention needs to be directed to their safety and development of long term side effects and new indications of these medications. Actually other biologic therapies have been study for the use in psoriasis like Infliximab, monoclonal antibody that blocks the action of TNFα.

REFERENCES

1. Enno E, Ulrich M. Psoriasis. En: Freedberg Irwin, Eisen A, Wolff K, et al. editors. Fitzpatrick´s Dermatology in General Medicine. Volumen I. 5 Ed. New york. Mc Graw Hill 1999. pp. 495-521.

2. Rizova E, Corroller M. Topical calcitriol studies on local tolerance and systemic safety. Br J Dermatol 2001;144:3–10.

3. Barker J, Gollnick H, Berth J. Treatment of Psoriasis with vitamin D3 derivates and 311nm UVB. J Dermatol Treatment 1998;9: 1–7.

4. Bowcock AM, Barker JN. Genetics of psoriasis: the potential impact on new therapies. J Am Acad Dermatol 2003;49:s51-s56.

5. Lebwohl M, Suad A. Treatment of Psoriasis Part 2. Systemic therapies. J Am Acad Dermatol 2001;45:649–673.

6. Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003;49:s44-s49.

7. Robert C, Kupper T. Inflammatory skin diseases T cells, and immune surveillance. N Engl J Med 1999;341:1817-1828.

8. Krueger J. The immunologic basis for the treatment of Psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1-23.

9. Callen JP.New psoriasis treatments based upon a deeper understanding of the pathogenesis of psoriasis vulgaris and psoriatic arthritis: A personal appraisal of their use in practice. J Am Acad Dermatol 2003;49: 351-356.

10. La cava A. Cytokines and autoimmune rheumatic disease. Int J Adv Rheumatol 2003;1: 10–19.

11. Gottlieb A. Immunobiologic agents for the treatment of psoriasis. Arch Dermatol 2003;139:791-792.

12. Goffe B, Catre JC. Etanercept: An overview. J Am Acad Dermatol 2003;49:s105-s111.

13. Smith K, Skelton H. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha IgG-Fc fusion complex therapy J Am Acad Dermatol 2001;45:953-6.

14. LaDuca JR, Gaspari AA. Targeting tumor necrosis factor alpha. Dermatol Clin 2001;19:617-31.

15. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB. Etanercept monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22.

16. Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge D. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000;356:385-90.

17. Krueger GG, Callis K. Development and use of alefacept to treat Psoriasis. J Am Acad Dermatol 2003;49:s 87-s97.

18. Callen JP. New psoriasis treatments based upon a deeper understanding of the pathogenesis of psorisis vulgaris and psoriatic arthritis: A personal appraisal of their use in practice. J Am Acad Dermatol 2003;49:351-56.

19. Lebwohl M, Christophers E, Langley R, Ortonne J, Roberts J, Griffiths C. An international, Randomized, Doubledblind, Placebo-controlled Phase 3 Trial of Intramuscular Alefacept in patients with chronic plaque Psoriasis. Arch Dermatol 2003;139:719-27

20. Gottlieb AB, Casale T, Frankel E, Goffe B, Lowe N, Ochs Hans D et al. CD4+ T-celldirected antibody responses are maintained in patents with psoriasis receiving alefacept: Results of a randomized study. J Am Acad Dermatol 2003; 49:816-25.

21. Gottlieb A. Infliximab for psoriasis. J Am Acad Dermatol 2003; 49:s112–s117.

22. Weaver A. Differentiating the new rheumatoid arthritis biologic therapies. J Clin Rheumatol 2003; 9:99-114.

23. Lebwohl B, Sapadin A. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2003;49: s275-s276.

24. Kaplan N, Palmer B. New indications for the treatment of chronic inflammation by TNFα blockade. Am J Med Sc 2003;325:75-92.

25. Gottlieb A, Masud S, Ramamurthi R, Abdulghani A, Romano P, Chaudhari U, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factorα monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003;48:68-75.

26. Gottlieb A, Chaudhari U, Mulcahy L, Li Shu, Dooley L, Baker D, et al. Infliximab monotherapy provides rapid and sustained benefit plaque-type psoriasis. J Am Acad Dermatol 2003;48:829-835.

27. Feleter M, Brockbank JE, Schentag T, Lapp V, Gladman DD. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 2004;63:156-161.

28. Leonardi C. Efalizumab: An overview. J Am Acad Dermatol 2003;49:s98-s104.

29. Gordon K, Papp K, Hamilton T, Walickle P, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psosiasis. JAMA 2003;290:3073-3080.

30. Lebwohl M, Tyring S, Hamilton T Toth D, Glazer S, Tawfik N et al. A novel targeted T cell modulator, efalizumab, for palque psoriasis. N Engl J Med 2003;349:2004-13.